Mode
Text Size
Log in / Sign up
N/A N=46 Randomized Treatment

Percutaneous Interruption of the Coracohumeral Ligament for the Treatment of Frozen Shoulder

Adhesive Capsulitis

Enrolled (actual)
46
Serious AEs
8.7%
Results posted
May 2024
Primary outcome: Primary: Comparison of Range of Motion of the Shoulder — 61; 49; 80; 64 degrees

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Tenex (Device); Local anesthetic (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Albert Einstein College of Medicine
Primary completion
Mar 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Comparison of Range of Motion of the Shoulder
61; 49; 80; 64
SECONDARY
Durability of Local Anesthetic - Change in Range Of Motion (ROM)
29; 32; 53; 57
SECONDARY
Durability of the TENEX - Change in Range Of Motion (ROM)
63; 62; 78; 77
SECONDARY
Change of Pain Intensity Score for Local Anesthetic Group
8; 8
SECONDARY
Change of Pain Intensity Score for TENEX Group
8; 3
SECONDARY
Change of the Oxford Shoulder Score for Local Anesthetic Group
10.8; 13.8
SECONDARY
Change of the Oxford Shoulder Score for TENEX Group
7.4; 31.8

Summary

Percutaneous Interruption of the Coracohumeral Ligament for the treatment of Frozen Shoulder.

Eligibility Criteria

Inclusion Criteria

  • Established Diagnosis of Adhesive capsulitis (AC) Ligament Flavum >3mm, diagnosed by US evaluation decreased shoulder ROM in external rotation and abduction (50% of unaffected side)
  • Patients who have tried other conventional therapies like steroid treatments, surgical treatments, physiotherapy with little (defined by less than 20 degrees improvement in shoulder ROM - external rotation) to no improvement in the shoulder ROM

Exclusion Criteria

  • Age less than 18 years and greater than 89 years
  • Patients with AC but showing improvement in shoulder ROM progressively (defined by improvement in ROM > 200 external rotation or 20 degrees per week when undergoing physiotherapy)
  • Patients who are currently pregnant
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04549051). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search